Companion diagnostics trend will make Rx look at in-house Dx anew
This article was originally published in Clinica
Executive Summary
Medium-sized and niche players – more than global concerns – have been driving most of the IVD industry’s engagement with pharma on joint companion diagnostics (CDx) projects so far. But with personalised medicine increasingly ingrained in the healthcare business psyche, it is likely that the pharma sector will henceforth exploit the emerging business opportunities most keenly. A new report from PwC describes the rationale behind this. Ashley Yeo reports